Combining a BCL2 Inhibitor with the Retinoid Derivative Fenretinide Targets Melanoma Cells Including Melanoma Initiating Cells

Investigations from multiple laboratories support the existence of melanoma initiating cells (MICs) that potentially contribute to melanoma's drug resistance. ABT-737, a small molecule BCL-2/BCL-XL/BCL-W inhibitor, is promising in cancer treatments, but not very effective against melanoma, with...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukherjee, Nabanita, Reuland, Steven N., Lu, Yan, Luo, Yuchun, Lambert, Karoline, Fujita, Mayumi, Robinson, William A, Robinson, Steven E, Norris, David A., Shellman, Yiqun G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323853/
https://www.ncbi.nlm.nih.gov/pubmed/25350317
http://dx.doi.org/10.1038/jid.2014.464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323853/
https://www.ncbi.nlm.nih.gov/pubmed/25350317
http://dx.doi.org/10.1038/jid.2014.464

Ejemplares similares